Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker’s $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.
The offer for Spark shares now runs to Oct. 1, Roche said.
Around 24.1% of Spark’s outstanding shares had been tendered as of the end of August.
“The offer was extended to provide additional time for the U.S. Federal Trade Commission (the ‘FTC’) and the UK Competition and Markets Authority (the ‘CMA’) to complete their previously disclosed reviews of Roche’s pending acquisition of Spark. The parties remain committed to the transaction and are working cooperatively and expeditiously with the FTC and the CMA,” a statement said.
By Michael Shields
LinkedIn Twitter FacebookAfter three years at the helm of troubled drugmaker Endo, CEO Paul Campanelli shocked analysts in November with his announcement he would step away to the chairman role. […]
LinkedIn Twitter FacebookGilead Sciences has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Johnson & Johnson and the Dana-Farber Cancer Institute, who joins from Bristol-Myers […]
LinkedIn Twitter FacebookWe generate data about ourselves all the time, the acquisition and interpretation of which is big business. In many cases, this data may be fairly trivial or inconsequential. […]